Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice
EASL International Liver Congress
Site map
Contact us
Business Development
bd@sagimet.com
Investors
ir@sagimet.com
Media
media@sagimet.com
Human Resources
hr@sagimet.com
© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice